CA-MANSCAPED
22.10.2020 15:02:07 CEST | Business Wire | Press release
Male grooming. In this day and age, these two words can - and should - mean trimming and tidying up all areas of a man’s body, including the nether regions. You may have thought about it, or even partaken in this all-important activity and reaped the results! But was it as enjoyable as it was effective? And, more importantly, were you equipped with the right tools for the job?
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022005418/en/
If you are not already familiar with the pioneer below-the-waist grooming and hygiene brand , let us formally introduce you to MANSCAPED™ . This California-based startup has single-handedly disrupted the men’s grooming industry and created a completely new category in the consumer packaged goods space.
Born in 2016, the booming direct-to-consumer (DTC) company designs and develops premium products for groin and body grooming , while upholding a steadfast mission to empower the modern man to unabashedly grab ahold of his situation “down there”. We are proud to report that since inception, the stigma-shattering brand has utterly taken off.
Today, MANSCAPED announces its latest and most extensive expansion yet into the European Union , which augments its reach to 1 billion people worldwide . This follows successful international launches earlier this year into Canada, Australia, New Zealand, and the United Kingdom. With the holidays on the horizon, the perfect present or self-care treat is now just a click away for every lady and gentleman in more than 30 countries worldwide .
“Entering into Europe in one fell swoop is no small feat, but we’re confident we have the infrastructure and high-powered passion to fuel this momentous launch,” said Stephanie Hinze, MANSCAPED’s Senior Director of International Operations. “Sharing the European Union’s values of inclusion and non-discrimination, we believe our trusted brand and superior products have sparked a new era of well-being for all and will continue to propel a movement throughout the region. We’re particularly excited to have laid the groundwork just in time for the holiday season in order to offer only the best tools and formulations to so many more men and women throughout the world.”
If that news doesn’t excite consumers enough, this milestone is coupled with a new product launch that our international fans have been waiting for. That’s right, our very first above-the-waist tool * is now available in over 30 countries! Combine this groundbreaking device with our best-selling below-the-waist trimmer and skincare products, and you have a set of essentials that is a must-have for the men on your list...
Introducing The Performance Package , our newest luxury grooming kit that includes:
The Lawn Mower™ 3.0 - The legendary electric trimmer for the groin and body is the cornerstone of a refined grooming routine. The precision engineered device boasts a 7,000 RPM motor with QuietStroke™ technology and replaceable ceramic blade with MANSCAPED’s SkinSafe™ technology that helps reduce the risk of nicks, cuts, and snags. The 600mA Li-Ion rechargeable battery and waterproof ergonomic design allows for a safe and easy trimming session.
*The Weed Whacker™ - Now Available Internationally - This revolutionary electric ear and nose hair trimmer is a technological masterpiece, redesigning the traditional nose hair taming tool by focusing on maximum performance and comfort, and offering a sleek, ultramodern design. The tool features SkinSafe technology, a 9,000 RPM motor and 360-degree rotary dual-blade system, and intelligently contoured design.
Crop Preserver™ - Ball deodorant is a thing, and it’s life-changing. The anti-chafing formula is infused with cooling aloe vera and controls any stench coming from an unwanted “swamp crotch”.
Crop Reviver™ - This innovative ball toner is the solution for maintaining hygiene and cleanliness on-the-go. The restorative spray relieves high-friction areas and post-shave irritation with just a spritz or two.
As a leading DTC brand, MANSCAPED offers a one-stop-shop online where customers can browse the full collection and purchase items a la cart or as part of a bundle - all with guaranteed free shipping. For our new consumers residing in Europe, please visit eu.manscaped.com to learn more and join the MANSCAPED Movement today!
About MANSCAPED™:
Founded in 2016, San Diego, California-based MANSCAPED is the global leader in men's grooming and hygiene below-the-waist. The product range includes only the best tools, formulations, and accessories for a simple and effective male grooming routine. MANSCAPED offers direct-to-consumer shipping in more than 30 countries, spanning the United States, Canada, Australia, New Zealand, the United Kingdom, and the European Union. Retail placement includes Target and Best Buy locations throughout the U.S., with further retail availability coming soon. MANSCAPED.com is a one-stop shopping destination for men looking for a brand that is focused on the needs of what has, for too long, been a sensitive and often taboo subject. For more information, visit the website or follow on Facebook , Instagram , Twitter , TikTok , YouTube , and Triller.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005418/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom